USING POLYMERIC SCAFFOLDS FOR VASCULAR TISSUE ENGINEERING by Abruzzo, A. et al.
Review Article
Using Polymeric Scaffolds for Vascular Tissue Engineering
Alida Abruzzo,1,2 Calogero Fiorica,3 Vincenzo Davide Palumbo,1,2,4 Roberta Altomare,1,2
Giuseppe Damiano,4 Maria Concetta Gioviale,4 Giovanni Tomasello,2,4 Mariano Licciardi,3
Fabio Salvatore Palumbo,3 Gaetano Giammona,3 and Attilio Ignazio Lo Monte1,2,4
1 PhD Course in Surgical Biotechnology and Regenerative Medicine, University of Palermo, Via Del Vespro, 129 90127 Palermo, Italy
2 Dichirons Department, University of Palermo, Via Del Vespro, 129 90127 Palermo, Italy
3 Department of Biological, Chemical, Pharmaceutical Sciences and Technologies, University of Palermo,
Viale delle Scienze, 16 90128 Palermo, Italy
4 “P. Giaccone” Universitary Hospital, School of Medicine, School of Biotechnology, University of Palermo,
Via Del Vespro, 129 90127 Palermo, Italy
Correspondence should be addressed to Attilio Ignazio Lo Monte; attilioignazio.lomonte@unipa.it
Received 6 February 2014; Accepted 9 June 2014; Published 21 July 2014
Academic Editor: Xiaoming Li
Copyright © 2014 Alida Abruzzo et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
With the high occurrence of cardiovascular disease and increasing numbers of patients requiring vascular access, there is a
significant need for small-diameter (<6mm inner diameter) vascular graft that can provide long-term patency. Despite the
technological improvements, restenosis and graft thrombosis continue to hamper the success of the implants. Vascular tissue
engineering is a new field that has undergone enormous growth over the last decade and has proposed valid solutions for blood
vessels repair. The goal of vascular tissue engineering is to produce neovessels and neoorgan tissue from autologous cells using a
biodegradable polymer as a scaffold. The most important advantage of tissue-engineered implants is that these tissues can grow,
remodel, rebuild, and respond to injury. This review describes the development of polymeric materials over the years and current
tissue engineering strategies for the improvement of vascular conduits.
1. Introduction
Each year there is a strong demand for vascular grafts due
to arteriosclerosis and other cardiovascular diseases that are
the main cause of mortality in the western countries [1–
4]. Nowadays, autotransplantation of blood vessels is usually
performed; however, the possible presence of vein diseases
and a limited availability of autologous blood vessels make
this procedure often impracticable [5, 6]. This necessity has
led to the use of nonbiodegradable synthetic prostheses and,
more recently, to the approach of tissue engineering. Vascular
tissue engineering has been described as “an interdisciplinary
field that applies the principles and methods of engineering
and the life sciences towards the development of biological
substitutes that restore, maintain, and improve tissue func-
tion” [7]. Its aim is to develop biocompatible scaffolds that
mimic the mechanical properties of autogenous conduits,
while providing a framework for guided cell repopulation
creating a functional cardiovascular conduit [8]. The tissue
engineering approach starts from the isolation of specific
cells, their growth on a three-dimensional biomimetic scaf-
fold under controlled culture conditions, the delivery of the
construct to the desired site, and the direction of new tissue
formation into the scaffold while it is degraded [9]. Thus,
tissue engineering usually uses three components to achieve
its outcomes: (a) cells, (b) scaffolds or matrices to provide
a template for tissue ingrowth, and often with the addi-
tion of (c) environmental factors (such as compression, shear
stresses, and a pulsatile flow in the case of arterial tissue engi-
neering) and/or growth factors or morphogens (physical or
chemical factors inducing tissue healing and cell differentia-
tion) [10, 11].
Clearly, the scaffold must be produced on the basis of
morphological, physiologic, andmechanical properties of the
tissue that need to be regenerated which has to be studied
from the anatomical point of view [12]. The wall of a blood
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vessel is constituted by three main layers called tunica adven-
titia, tunica media, and tunica intima. The outermost layer is
the tunica adventitia which is mainly composed by fibroblast
and elastin and supply mechanical strength and integrity.
Tunicamedia is composedmainly by smoothmuscle cells
and elastin and is responsible for the viscoelastic behavior of
the vessel. Tunica intima is the inner part of the vessel in con-
tact with the circulating blood and is composed of a single
layer of endothelial cells mounted on a basement membrane
[2, 13]. Synthetic scaffolds which are intended to mimic
the structure of a blood vessel must promote the correct
orientation of the different cell types as well as the main-
tenance of the structural integrity and the long-term patency
[14]. In this review, the developments made in the field of
replacement of damaged blood vessels from the early surgical
approaches to the innovative approach of tissue engineering
will be discussed. Particular attention will be given to the use
of polymeric materials and to the techniques of production
of biomaterials that allow to mimic the morphological char-
acteristics of the blood vessels.
2. From the Early Surgical Approaches to
the Nonbiodegradable Grafts
The gold standard material for blood vessels replacement,
because of the complex histological structure of this partic-
ular tissue, is represented by blood vessels themselves. For
this reason the first surgical approaches were oriented to the
autologous vessels transplantation [15]. The first approach to
the problem of replacing a damaged vascular tract was dated
in 1906, when for the first time a venous autograft was used
as replacement of a section of an artery. It was Jose´ Goyanes
who, on the occasion of a popliteal aneurysm, removed the
damaged part of the artery and connected the cut ends using
a section of the autologous popliteal vein.The patient showed
an infection after the operation, but this must be probably
caused by the injection of gelatin in the popliteal cavity before
the operation, rather than implanting the graft. The subject
was hospitalized and did not revealcirculation problems [16,
17]. In 1915, Bernheim provided another approach to repair
popliteal aneurysm. The patient in this case had to undergo
the removal of about 15 cm popliteal artery, replaced by 12 cm
of the saphenous vein [18].
Other case studies were followed, but the two previous
cases had considerable importance, as it was from here that
came the idea of reconstructing a damaged tissue [19]. The
major example of autologous implant is the saphenous vein,
which consists of one of the two larger ducts venous lower
limb together with the femoral vein and has a diameter
generally between 4 and 6mm. The clear advantage of using
this vessel is that it evokes no rejection and showsmechanical
characteristics comparable to arteries [20]. In 1948 Kunlin
created a femoropopliteal bypass with a system consisting
of the reversed saphenous vein, laying the foundation for
a practice that is still to be established. In the same year
early arterial systems began to spread consisting of foreign
tissue but deriving from subjects of the same species [21].
Unfortunately, this approach is burdened by high failure rates,
as in the case of saphenous vein graft, due to atheroscle-
rosis and intimal hyperplasia of the transplanted vessels
[22]. Furthermore, it was showed that almost 30–40% of
patients lack an appropriate saphenous vein [23, 24] due
to previous phlebitis, vessel removal, varicosities, hypopla-
sia, or anatomical unsuitability [25]. There has been also
an experimentation of homologous saphenous vein grafts
(homograft), but there were no encouraging results in terms
of physical and mechanical characteristics. In addition, there
were frequent phenomena of rejection and deterioration,
and it is supposed that the patency of the conduit remains
unaltered only for vessels of diameter greater than 5mm. For
these reasons, in 1960 the homograft was abandoned [26].
Autologous arteries (internal and external iliac, superficial
femoral, and internal mammary) were ideal artery bypass
in the cardiac and the peripheral arteries but both had
a limited availability of sites donors [27]. Because of the
excellent long-term patency, the internal mammary artery
was considered to be the best choice for coronary artery
bypass graft in younger patients. For other patients, when
the internal mammary was not available or not indicated, the
alternative was represented by the right gastric or intercostal
arteries [28]. The possible presence of vein diseases and a
limited availability of autologous blood vessels represent the
major limitation to the autologous transplantation that has
led to the necessity to develop artificial blood vessels [29].
Currently expanded polytetrafluoroethylene (ePTFE)
and Dacron (polyethylene terephthalate fibre) have been the
most widely used synthetic materials for realizing grafts [30].
Dacron is one of the trade names of PET (polyethylene
terephthalate) polymer belonging to the family of thermo-
plastic polyesters. The Dacron is resistant, deformable, and
biostable and is present in different forms. It is used in
cardiovascular surgery to achieve large-diameter vascular
prostheses, for arterial sutures and for the construction of the
valve rings. The highly crystalline and hydrophobic natures
of Dacron both prevent hydrolysis of a graft, leading to a
potential of residing inside the human body for decades. PET
is usually transformed fibers, from its linear macromolecules
with an average weight of about 20000Da. Each wire that
constitutes the prosthesis is composed by the association
of monofilaments obtained by passage of polymers fused
of PET in a supply chain. These wires are then elongated
by heat treatment capable of conferring aspect ring. Sub-
sequently, the individual filaments are gathered (spiral or
helix) in a single fiber. The fact of being multifilament
makes the fiber elastic and manageable. The wire weaved
is used to fabricate woven or knitted prosthesis [31]. Teflon
is a polymer of tetrafluoroethylene and is identified also as
polytetrafluoroethylene (PTFE). It is the most important and
used between polymers composed of fluorine and carbon.
In the 60’s, deriving from Teflon technolgy, PTFE foam
(ePTFE), also known as Gore-tex,was developed. It has found
application in vascular prostheses in the second half of the
70’s. Again, just like in Dacron, the highly crystalline and
hydrophobic nature yields a stable product by preventing
hydrolysis. Tubular grafts made from ePTFE are produced by
an extrusion, drawing, and sintering process and consist of
fibrils and nodules, controllable to different pore sizes. The
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Gore-Tex is therefore a nondegradable porous polymer with
a surface electronegative, which limits the reaction with the
components of the blood. It is biostable and in fact has a
lesser tendency, for example, to deteriorate in a biological
environment compared to PTFE. In general, however, the
behavior that it has in a biological environment is influenced
by the type of processing to which it is subjected.
In previous experiments it was found that the larger the
porosity of the material, the better is its integration with
the physiological environment. However, it was found that
an implant characterized by high porosity resulted to be
also fragile and therefore cannot be used clinically. In a
significant study conducted by Isaka et al. [32] a highly porous
graft was achieved but it was biocompatible and with the
ability to integrate in host tissues. The graft was inserted
in the abdominal aorta of eleven purebred dogs of both
sexes with a weight between 10 and 12 kg. In the graft used
the average internodal distance was 60m and the structure
showed tortuous channels formed by the nodes and fibrils of
PTFE. The implant was 30–40mm long; its inside diameter
measured 6mm and was reinforced by a filament fluoroethy-
lene propylene. The eleven grafts were then inserted into the
animals and extracted at intervals of 2 weeks (4 grafts), 4
weeks (4 other grafts), and 80weeks (3 graft). On the implants
removed an evaluation of the resistance to radial tension,
longitudinal tension, the retention force of the suture, and
the rate of deformation was performed. The results showed
that there was no sign of any problems or occlusion at
the level of anastomosis. The rate of deformation demon-
strates a certain stability of the two properties considered.
Furthermore, as regards the retention force of the suture,
there was no substantial difference between before and after
graftings. Additional experiments demonstrated that ePTFE
and Dacron were successful in large-diameter (>5mm) high-
flow vessels, but in low flow or smaller diameter sites they are
compromised by thrombogenicity and compliancemismatch
[33]. In the 80’s and 90’s, however, the performance of grafts
was evaluated with porosity gradually higher, starting from
the assumption that large pores permit a fast growth of tissue
from the outside of the graft upwithin its interstices, allowing
a large integration of the prosthesis with the biological
environment. Another category of polymers with large dif-
fusion is represented by polyurethanes. Polyurethanes were
originally developed commercially in Germany in the 1930s
as surface coatings, foams, and adhesives. Segmented PUs are
copolymers comprising 3 differentmonomers, a hard domain
derived from a diisocyanate, a chain extender, and a soft
domain, most commonly polyol. The soft domain is mainly
responsible for flexibility, whereas the hard domain imparts
strength. Polyether urethane was relatively insensitive to
hydrolysis but susceptible to oxidative degradation.
Polyurethane grafts which have been available for the
last 40 years have characteristics that would be ideal for use
in bypass procedures, namely, similar compliance to native
arteries with a surface that is conducive for seeding [34–37].
Unfortunately, polyurethane grafts have had variable results
clinically with a tendency to degrade causing aneurysm
formation [38]. Data obtained showed that when compared
with ePTFE grafts, the PUgraft overall showedno appreciable
difference in interval patency in canine aorticmodel. Further-
more, in a small study, the grafts were implanted in aortoiliac
arteries of 4 dogs for 6 months evidencing that luminal
thrombus affected 59% of polyurethane graft surfaces com-
pared to 22% of ePTFE graft [39]. Anyhow, tissue reactions
to PU grafts are discrepant in the literature because factors
such as different compositions of polymers, graft fabrication,
porosity, and surface modifications all affect the results. On
the basis of these evidences no conclusion can be made as to
whether PU grafts may be functionally superior to ePTFE or
Dacron grafts until more data become available.
3. Synthetic Prosthetic Grafts Disadvantages
and Diffusion of Tissue Engineering
It has been tested that currently available vascular grafts
show satisfactory long-term patency rates only in large-
caliber arteries (>8mm), where a massive blood flow may
overcome the risk of thrombogenicity. In medium-caliber
replacements (6–8mm), for example, in carotid or common
femoral arteries [40], a little difference between prosthetic
and autogenous material has been reported.
However, in small-caliber vessels (<6mm), such as coro-
nary arteries, infrainguinal arteries (below the inguinal liga-
ment), and particularly in low-flow infrageniculate arteries,
the outcomes of vascular prostheses are unsatisfactory.
Several methods have been developed to enhance the
patency rates. The major example is the linking of heparin
to graft surfaces in order to obtain a reduction of the
thrombogenic activity [37, 41]. Nevertheless this strategy
is associated with the problem of the duration of hep-
arin activity due to premature release of the compound
or the presence of a physical barrier, created by adherent
blood components. Other modifications are the coating of
the luminal surface with carbon so that electronegativity
is improved and thus thrombus formation reduced [42].
Another widely used coating material is fibrin glue, which
is able to improve endothelialization and other physical and
chemical variations [43, 44]. Additionally, synthetic grafts are
usually rejected within few months by the immune system
of the body if the diameter of the vessel is smaller than
6mm. This rejection arises from the consequent reocclusion
caused by thrombosis, aneurysm, and intimal hyperplasia
due to mismatch of compliance (compliance is the opposite
of stiffness, measured as the strain/expansion or contraction
of the graft with force) [45–50]. Thrombogenicity could be
associated with the deposition of fibrin and platelets on the
surface of an implanted material or with the proliferation
of smooth muscle cells, which migrate from native vessel,
invade the intima by growing instead of endothelial cells,
and produce extracellular matrix [51]. Intimal hyperplasia
(IH) is located at distal anastomosis of prosthetic grafts and
generally developed 2–24 months after implantation and
includes a variety of factors: a compliance mismatch between
a relatively rigid prosthesis and the more elastic native artery
[52], graft/artery diameter mismatch, lack of endothelial
cells, surgical trauma and flow disturbances resulting in
adaptive changes in the subendothelial tissue, characterized
by proliferation and migration of vascular smooth muscle
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cells from media to intima, and synthesis of extracellular
matrix (ECM) proteins. To overcome these issues, novel
biomaterials research [53] and particularly tissue engineer-
ing modalities are increasingly being adopted [54]. Tissue
engineering opened the way to the creation of devices with
an adequate mechanical strength and compliance in order
to withstand long-term hemodynamic stresses; furthermore,
these devices should be nontoxic, nonimmunogenic, biocom-
patible, available in various sizes for emergency care, resistant
to in vivo thrombosis, and able to withstand infection and
to incorporate into the host tissue with satisfactory graft
healing [55], related with reasonable manufacturing costs
[27].
It is thought that tissue engineering would be particularly
valuable in the production of vascular grafts because of the
massive need and precarious supply of natural graft material
for clinical use.
The challenges faced by the approach of tissue engineer-
ing for replacing blood vessels are substantial. They include
providing an elastic vessel wall that canwithstand cyclic load-
ing, matching the compliance of the graft with the adjacent
host vessel, and a lining for the lumen that is antithrombotic
[56]. From the first production of completely biological
tissue-engineered blood vessels, composed of intima, media,
and an adventitia, using culturedmature smoothmuscle cells
and endothelial cells in bovine collagen gels byWeinberg and
Bell [57], there have been many attempts for successful blood
vessel construction through tissue engineering approach.
Various strategies including in vitro endothelization of the
graft have been used to overcome these problems but few in
vivo results have been obtained [58, 59]. It is now clear that an
intact luminal EC monolayer imparts resistance to thrombus
formation and reduces the extent of intimal hyperplasia [60].
Several studies revealed that when blood comes into
contact with another surface than the endothelium, there
is an elevated risk of thrombosis. These conditions can be
related also with loosely attached ECs that can detach right
after implantation due to blood flow related shear stress [61].
The EC layer is also able to inhibit actively thrombosis. This
is achieved by thrombomodulin receptors, heparin sulfate,
proteoglycans, and the secretion of NO, prostacyclin, protein
S, and t-PA, all of which inhibit the clotting process. Aside
from these features, the endothelium has a primary role in
blood pressure regulation, angiogenesis, and adhesion and
transmigration of inflammatory cells. It is therefore con-
sidered a vital component for maintaining good long-term
patency. ECs, however, have limited capacity for regeneration
and exhaust their renewal after approximately 70 cell cycles,
leading to the hypothesis that endothelialization of vascular
grafts occurs via one of four mechanisms: (i) by seeding ECs,
(ii) via ECmigration from adjacent native vessel, (iii) through
deposition of circulating endothelial progenitor cells onto the
luminal surface, or (iv) via ingrowth of capillaries through
porous grafts [62]. Since Herring proposed amethod of seed-
ing ECs onto the luminal surface of synthetic conduits back in
1978 [63, 64],many studies have attempted to improve clinical
rates of patency by optimizing EC attachment. Parallel to
this, in scaffold-based blood vessel engineering, bioreactors
and pulsatile flow systems, designed by many scientists,
have been found to progress the mechanical property of the
engineered blood vessels by augmenting the deposition and
remodeling of extracellular matrix as well as the maturation
and differentiation of self-assembled microtissues [65–68].
4. Tissue-Engineered Vascular Grafts
According to the tissue engineering approach a bioengi-
neered tissue should be able to act as a temporary prosthesis
that replace a particular damaged tissue for the time neces-
sary to the cells, seeded in it or coming from the sites proximal
to the implant, to synthesize a new extracellular matrix
contributing to the production of a new tissue. The choice
of the starting biomaterial is crucial as it influences the rate
of degradation in vivo, the structural and functional integrity
of the bio engineered tissue, and its gradual elimination
from the body. The starting biomaterial also influences the
mechanical properties of bioengineered tissue as well as its
ability to be recognized as “self ” by the body.This last feature
is particularly important and can be completed only if the
biomaterial carries biological signals that represent a stimulus
for the adhesion and proliferation of the cells as well as for
the production of new extracellular matrix. In other words,
the physical-chemical characteristics of the biomaterial are
able to influence the biochemical gap between living tissue
and bioengineered ones. In some cases the biomaterial itself
can represent a stimulus for the cellular functions (especially
when natural components of the extracellular matrix are
employed), while in most cases molecules such as growth
factors, adhesion moieties, or even drugs of various nature
have to be incorporated into bioengineered tissue by physical
mixing or covalent bond. In this last case the biomaterial
must have free functional groups to be exploited for the
functionalization with one or more bioactive molecules.
In blood vessels tissue engineering heparin and vascular
endothelial growth factor (VEGF) are widely used. Both are
in fact able to avoid the formation of thrombotic phenomena
due to blood clotting. Heparin has anticoagulant activity
and is crucial in the early stages after implantation, whereas
VEGF, promoting endothelial cell proliferation, permits the
formation of an intact endothelium on the surface of the
scaffold in contact with the circulating blood avoiding the
creation of turbulent motions responsible of the formation of
thrombi. Moreover the presence of a confluent monolayer of
endothelial cells prevents the development of pseudointimal
hyperplasia by inhibition of bioactive substances responsible
for SMC migration, proliferation, and production of ECM
[69]. Since the early vascular tissue engineering has spread-
ing, natural or synthetic polymers (or combination of the
two classes) have been used as starting materials. Polyesters
are a class of synthetic macromolecules widely used in tissue
engineering because of their optimal mechanical properties,
biocompatibility, and biodegradability.
These polymers have been used as sutures [70] plates and
fixtures for fracture fixation devices [71] and scaffolds for cell
transplantation [72, 73].
Polyesters such as poly(𝜀-caprolactone) (PCL), polylactic
acid (PLA), and polyglycolic acid have been approved by FDA
and extensively employed in experimental trials.
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Figure 1: Tubular PHEA-PLA-PCL scaffold.
Concerning the vascular tissue engineering polyesters
have been chosen as starting material very often thanks also
to their good processability. Among the manipulation tech-
niques electrospinning has gained great attention because
it offers the possibility to obtain scaffolds with a defined
shape and a complex porous architecture that can mimic the
three-dimensional structure of extracellular matrix offering a
good support for cell attachment and proliferation [74, 75].
Through electrospinning it is possible to prepare nonwoven
mats of polymer fibers with diameters ranging from several
microns down to less than 100 nm [76, 77]. Spun mats show
amazing characteristics such as very large surface area to vol-
ume ratio, flexibility in surface functionalities, and superior
mechanical performance (e.g., stiffness and tensile strength)
compared with any other known form of the material [78].
These outstanding properties make the polymer fibers be
optimal candidates in tissue engineering as substitutes of
several tissues [79]. Nottelet et al. [80] developed a PCL-
based vascular graft with an internal diameter of 2 or 4mm.
They implanted the cell-free scaffolds to Sprague-Dawley rats
in substitution of an infrarenal abdominal aorta portion to
evaluate the resistance and the patency of the implanted
scaffolds over a period of 12 weeks. Scaffolds showed good
surgical handling and suture retention properties and led to
successful implantations without thrombosis or aneurysm
formation at the three different time points. Authors observed
also an almost complete endothelial coverage to the endolu-
minal graft surface after 6 weeks of implantation but some
intima hyperplasia formation was observed in all grafts after
12 weeks.
Infiltration of fibroblast and macrophages was observed
through all the scheduled times indicating the presence of
an inflammation process even if no chronic lymphocytic
reaction was observed.
The in vivo result of this study was even encouraging and
has outlined the outstanding properties of PCL even if it is
clear that some drawbacks are still present to be solved. As
mentioned above, an ideal bioengineered tissue should opti-
mally integrate with native tissues exploiting the possibility
to be functionalized with bioactive molecules. The lack of
functional groups in the starting biomaterial able to pro-
mote this type of functionalization could represent a major
limitation. The small number of functional groups in the
chemical structure of the polyesters limits the possibility to
bind significant amounts of most of the bioactive agents and
only molecules able to perform their biological function even
at very low concentrations could be used.
Zheng et al. [81] produce a nanofibrous vascular graft by
electrospinning of PCL functionalized with an arginine-gly-
cine-aspartic acid-(RGD-) containing molecule named Nap-
FFGRGD.
They also produce RGD free PCL grafts and compared
results obtained from the implantation of the obtained
vascular scaffolds in rabbit. Both grafts implanted in rabbit
carotid arteries for 2 and 4 weeks showed endothelial cell
adhesion in the lumen of the scaffold even if on the RGD-
PCL cells were confluent and highly aligned, whereas those
on the RGD free PCL graft were randomly aligned.
The endothelialization rates for RGD-PCL grafts were
faster than those of the PCL grafts demonstrating the impor-
tance to incorporate the active molecule in the vascular graft.
Polyesters could be employed also in combination with
bioactive macromolecules (mostly of natural origin) having a
direct effect on the cells or with polymers having functional
groups exploitable for the binding with the molecules of
interest.
Pitarresi et al. [82] electrospun a mixture of PCL
and 𝛼,𝛽-poly(N-2-hydroxyethyl) (2-aminoethylcarbamate)-
D,L-aspartamide-graft-polylactic acid (PHEA-EDA-g-PLA),
a synthetic graft copolymer having in its chemical structure
several free primary hydroxyl and amino groups coming
from the hydrophilic backbone of PHEA-EDA, a biocompat-
ible polymer derived from PHEA which is widely employed
for several biomedical application [83–88] (Figures 1 and 2).
PHEA-EDA-g-PLA functional groups were exploited to
covalently link a significant amount of heparin (36 𝜇g per mg
of scaffold) which has been employed to control the release of
fibroblast growth factor. Authors demonstrate that the pres-
ence of both heparin and growth factor influences the ability
of endothelial cells cultured in vitro upon the scaffold to
produce an intact endothelial layer. Jia et al. [89] electrospun
poly(L-lactic acid) (PLLA) in combination with collagen
in order to obtain a scaffold with the optimal mechanical
characteristic, due to the presence of the polyester, and able
to represent an optimum substratum for cell adhesion and
spreading thanks to the presence of collagen. They seeded
bonemarrow derivedmesenchymal stem cells (MSCs) on the
obtained nanofibers to investigate the capability of these cells
to differentiate into vascular endothelial cells when cultivated
with differentiatingmedium.Authors demonstrated that cells
grown on PLLA/Coll nanofibrous scaffolds differentiated
in endothelial cells showing cobblestone phenotype with
expression of vascular specific proteins such as the platelet
endothelial cell adhesion molecule-1 and Von Willebrand
factor.The use of stem cells in tissue engineering is becoming
increasingly popular because these cells can be extracted from
various sources and can proliferate in vitro and differentiate
into a series of mesodermal lineages, including osteoblasts,
chondrocytes, adipocytes, myocytes, and vascular cells [90–
93].
Among the polymers of natural origin, silk fibroin has
certainly attracted a lot of attention in the field of vascular
tissue engineering. Silk fibroin of silkworms is a commonly
available natural polypeptidic biopolymer with a long history
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(a) (b)
Figure 2: PHEA-PLA-PCL scaffold. (a) SEM, 8000x, (b) SEM, 5000x.
of applications in the human body as sutures. Increasingly,
silk fibroin is exploited in other areas of biomedical science,
as a result of new knowledge of its processing and properties
like mechanical strength, elasticity, biocompatibility, and
controllable biodegradability [94]. Silk based regenerated
vascular tissues are clinically used as flow diverting devices
and stents and in general [95, 96] the properties of silk
fibroin are particularly useful for tissue engineering [97].The
implantation of vascular graft of silk fibroin composites of
B. mori and transgenic silkworm into rat abdominal aorta
results in excellent patency (about 85%) after a year [98].
Wang et al. produced a fibroin scaffold consisting of silk
braided tubes coated (on both inside and outside surfaces)
by a film of fibroin cross-linked with poly(ethylene glycol)
diglycidyl ether (PEG-DE). Through freeze drying technique
authors were able to obtain micro- and nanoscale pores
distributed throughout the inner surface of the scaffold.
They tested the biocompatibility in vitro on fibroblasts
and human umbilical vein endothelial cells demonstrating
that the biomaterial causes no inhibitory effect on DNA
replication, cell adhesion, or proliferative activity. Cells in
fact were able to fully spread on the internal surface and
formed an interconnected network [99]. Liu et al. produced
sulfated silk fibroin (S-silk) by reaction with chlorosulphonic
acid in pyridine and used the obtained biomaterial to form
a scaffold by electrospinning technique. They found that
the anticoagulant activity of S-silk scaffolds was significantly
enhanced compared with silk fibroin nanofibrous scaffolds.
Also they demonstrated that both endothelial cells and
smooth muscle cells strongly attached to S-silk scaffolds and
proliferated well expressing some phenotype-related marker
genes and proteins [100].
Several other studies have been conducted by employing
natural derived polymers (also in combination with synthetic
polymers) for the development of tissue-engineered blood
vessels.
Zhu et al. developed a 3D scaffold for vascular tissue
engineering by employing hyaluronic acid (HA) and human
like collagen (HLC). A tubular structure was obtained by
cross-linking the polymers with glutaraldehyde and then by
freeze drying the obtained product previously placed in a
tubular mold. Authors demonstrated that the presence of
HA promotes endothelial cell proliferation and maintains
their viability. Furthermore, HA enhances the mechanical
properties of vascular hybrid scaffold [101].
5. Conclusions
Despite numerous in vitro and in vivo results obtained by
different research groups in the production of bioengineered
blood vessels, to the best of our knowledge, there are no
clinical applications of any of these devices.
This denotes a real difficulty of the transposition of the
implant from the animal model to humans and thus there is
still a need to develop devices able to recreate entirely the
functional properties of native blood vessels following the
principles of tissue engineering.
There are still many aspects to be explained before a real
clinical translation of vascular implants.
Further studies can help to clarify the mechanisms of
regeneration and may address towards the choice of a more
efficient strategy for scaffold production and cells seeding.
Understanding the role of inflammatory cells in blood
vessel regeneration, for example, could be of great importance
for the future development of innovative grafts.
It is also desirable to overcome the problem of thrombo-
genicity in humans, finding a new approach that can retain
endothelial cells on grafts for a sufficient period of time under
flow conditions in vivo.
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